Cytosorbents Corporation (CTSO)

Market Cap	54.68M
Revenue (ttm)	37.74M
Net Income (ttm)	-18.67M
Shares Out	54.68M
EPS (ttm)	-0.36
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	47,643
Open	1.030
Previous Close	1.000
Day's Range	0.990 - 1.070
52-Week Range	0.700 - 1.610
Beta	0.78
Analysts	Strong Buy
Price Target	4.67 (+367.0%)
Earnings Date	May 8, 2025

About CTSO

Cytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology in the United States, Germany, and internationally. Its flagship product is CytoSorb, an extracorporeal cytokine adsorber for adjunctive therapy in the treatment of sepsis, adjunctive therapy in other critical care applications, prevention, and treatment of perioperative complications, and maintaining or enhancing the quality of...

• Industry: Medical Devices
• Sector: Healthcare
• Founded: 1997
• Employees: 186
• Stock Exchange: NASDAQ
• Ticker Symbol: CTSO
• Website: https://www.cytosorbents.com

Financial Performance

In 2023, Cytosorbents's revenue was $36.35 million, an increase of 4.79% compared to the previous year's $34.69 million. Losses were -$28.51 million, -13.12% less than in 2022.

Analyst Forecast

According to 3 analysts, the average rating for CTSO stock is "Strong Buy." The 12-month stock price forecast is $4.67, which is an increase of 367.00% from the latest price.

Price Target

$4.67

(367.00% upside)

Analyst Consensus: Strong Buy